6IB 株式概要 バイオ医薬品会社であるイノベント・バイオロジクス社は、中華人民共和国において、がん、眼科、自己免疫疾患、心血管・代謝疾患分野におけるモノクローナル抗体およびその他の医薬品資産の開発・商業化を行なっている。 詳細
報酬 リスク分析 リスクチェックの結果、6IB 、リスクは検出されなかった。
すべてのリスクチェックを見る {"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
あなたの考え、リンク、会社の物語を記録する
Innovent Biologics, Inc. 競合他社 価格と性能
株価の高値、安値、推移の概要Innovent Biologics 過去の株価 現在の株価 HK$4.30 52週高値 HK$6.20 52週安値 HK$3.64 ベータ 0.23 1ヶ月の変化 3.37% 3ヶ月変化 0% 1年変化 4.88% 3年間の変化 19.44% 5年間の変化 8.04% IPOからの変化 115.00%
最新ニュース
Innovent Biologics, Inc. and Jiangsu Aosaikang Pharmaceutical Co. Ltd. Jointly Announce NMPA Approval of Limertinib, a Third-Generation EGFR TKI for the Treatment of Lung Cancer Jan 19
Innovent Biologics, Inc. Announces National Medical Products Administration of China Approves Second New Drug Application of DOVBLERON Jan 03 Innovent Biologics, Inc. announced that it has received funding from Xuhui Science and Technology Venture Capital Jan 01
Innovent Biologics, Inc. Receives Approval of DOVBLERON®? (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration Dec 20
Innovent Presents Updated Data from Innovative Anti-CLDN18.2 Adc (Ibi343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the Esmo Asia Congress 2024 Dec 09
Innovent Biologics, Inc. Announces First-Time Inclusion of SINTBILO and New Indication for Olverembatinib in China's National Reimbursement Drug List Nov 28 最新情報をもっと見る
Innovent Biologics, Inc. and Jiangsu Aosaikang Pharmaceutical Co. Ltd. Jointly Announce NMPA Approval of Limertinib, a Third-Generation EGFR TKI for the Treatment of Lung Cancer Jan 19
Innovent Biologics, Inc. Announces National Medical Products Administration of China Approves Second New Drug Application of DOVBLERON Jan 03 Innovent Biologics, Inc. announced that it has received funding from Xuhui Science and Technology Venture Capital Jan 01
Innovent Biologics, Inc. Receives Approval of DOVBLERON®? (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration Dec 20
Innovent Presents Updated Data from Innovative Anti-CLDN18.2 Adc (Ibi343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the Esmo Asia Congress 2024 Dec 09
Innovent Biologics, Inc. Announces First-Time Inclusion of SINTBILO and New Indication for Olverembatinib in China's National Reimbursement Drug List Nov 28
New major risk - Share price stability Nov 10
Forecast to breakeven in 2025 Oct 28
Co-Founder recently sold €9.5m worth of stock Oct 06
First half 2024 earnings released: CN¥0.24 loss per share (vs CN¥0.091 loss in 1H 2023) Sep 29
Innovent Biologics, Inc. Announces Acceptance of New Drug Application for Picankibart Injection by China's NMPA Sep 26
Innovent Biologics, Inc. Announces Clinical Data of IBI363 (First-in-class PD-1/IL-2a-bias Bispecific Antibody Fusion Protein) Combined with Bevacizumab in Advanced Colorectal Cancer at the 2024 ESMO Congress Sep 18
Forecast to breakeven in 2025 Sep 09
Innovent Biologics, Inc. Announces Change in Composition of Board Committees Aug 30
First half 2024 earnings released: CN¥0.24 loss per share (vs CN¥0.091 loss in 1H 2023) Aug 29
Innovent Biologics, Inc. Announces the Approval of Dupert® (Fulzerasib) by the National Medical Products Administration of China Aug 22
The National Medical Products Administration Approves Centre for Drug Evaluation of the National Medical Products Administration of China's First KRAS G12C Inhibitor Dupert Aug 21
Innovent Biologics, Inc. to Report First Half, 2024 Results on Aug 28, 2024 Aug 15
Innovent Biologics, Inc. and Sanegene Bio USA Inc. Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3016 (AGT siRNA) Aug 02
the National Medical Products Administration of China Accepts the New Drug Application of Mazdutide of Innovent Biologics, Inc Aug 01
Forecast to breakeven in 2025 Jul 29
Innovent Biologics, Inc. Presents the Results of the First Phase 3 Study of Mazdutide for Weight Management at the ADA's 84th Scientific Sessions Jun 25
High number of new directors Jun 02
Innovent Biologics, Inc. Announces Picankibart (IBI112) Achieved Primary Endpoints in A Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to the NDA to the NMPA May 29
Innovent Biologics Announces National Medical Products Administration of China Accepts the New Drug Application for IBI311 May 23
Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC) as Monotherapy for Advanced Gastric Cancer May 08
Full year 2023 earnings released: CN¥0.66 loss per share (vs CN¥1.46 loss in FY 2022) Apr 30
Innovent Biologics, Inc. Appoints Samuel Zhang as Global Chief Business Officer Apr 30
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status Apr 03
Innovent Biologics, Inc. Announces the National Medical Products Administration Accepts the New Drug Application Apr 02
Innovent Biologics, Inc., Annual General Meeting, Jun 21, 2024 Mar 21
Full year 2023 earnings released Mar 20
Innovent Biologics, Inc. Releases the Results of Two Clinical Studies of Ibi311 (An Anti-IGF-1R Monoclonal Antibody) in Oral Presentations At the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024 Mar 07
Anheart Therapeutics and Innovent Announces China’s NMPA Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of Ros1-Positive Lung Cancer Mar 06
Innovent Biologics, Inc. to Report Fiscal Year 2023 Results on Mar 20, 2024 Mar 01
Innovent Biologics, Inc. Announces the Phase 3 Clinical Study of Ibi311 Met the Primary Endpoint in Treating Thyroid Eye Disease Feb 20
Innovent Biologics, Inc. Announces Appointment of Shun Lu as Independent Non-Executive Director and A Member of the Strategy Committee Feb 10
Innovent Biologics, Inc.'s First New Drug Application of Mazdutide for Chronic Weight Management Has Been Accepted by the NMPA of China Feb 07 Innovent Biologics, Inc. Announces Chief Financial Officer Changes Feb 05
Innovent Biologics, Inc. Announces the First Phase 3 Clinical Trial of Mazdutide Inchinese Adults with Overweight or Obesity Metthe Primary and All Key Secondary Endpoints Jan 09
China’S National Medical Products Administration Grants Anheart Therapeutics and Innovent Biologics, Inc. Taletrectinib (Ros1 Inhibitor) Priority Review Designation for the New Drug Application (Nda) of Taletrectinib Dec 19
Innovent Biologics, Inc. Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications Dec 18
Innovent Biologics, Inc. Announces the Phase 3 Orient-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma Dec 08
Forecast to breakeven in 2025 Dec 04
Innovent Biologics, Inc. Announces the National Medical Products Administration of China Accepts and Grants Priority Review Designation to the New Drug Application for IBI351 Nov 25
Innovent Biologics, Inc. Announces Acceptance of New Drug Application from National Medical Products Administration for Taletrectinib Nov 23
Innovent Biologics, Inc Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Type 2 Diabetes in Diabetes Care Nov 22
The National Medical Products Administration Approves Olverembatinib for the Treatment of Cml-Cp Patients Nov 18
Innovent Biologics, Inc. Announces Robust Weight Loss Efficacy, Multiple Metabolic Benefits and Favorable Safety Profile of Higher Dose 9 mg Mazdutide (IBI362) after 48-week Treatment in Phase 2 Study for Obesity Oct 30
Innovent Biologics, Inc. Announces Update on the New Drug Application for Parsaclisib (PI3Kd Inhibitor) Sep 29
Now 20% undervalued Sep 26 Innovent Biologics, Inc. has completed a Follow-on Equity Offering in the amount of HKD 2.35688 billion. Sep 20
New minor risk - Shareholder dilution Sep 19
First half 2023 earnings released: CN¥0.091 loss per share (vs CN¥0.65 loss in 1H 2022) Aug 23
National Medical Products Administration Approves New Drug Application for Innovent Biologics, Inc.'s Sintbilo Aug 17
New major risk - Share price stability Aug 10
Innovent Biologics, Inc. to Report Q2, 2023 Results on Aug 23, 2023 Aug 08 IASO Bio and Innovent Announce the NMPA Approval of the New Drug Application for Equecabtagene Autoleucel, the World's First Fully-human BCMA CAR-T Therapy, for the Treatment of Relapsed and/or Refractory Multiple Myeloma
Innovent Biologics, Inc. Announces Phase 1 Clinical Data of IBI322 (CD47/PD-L1 Bispecific Antibody) in the Treatment of Anti-PD-(L)1-Resistant Classic Hodgkin Lymphoma Patients at the EHA 2023 Annual Meeting Jun 12 Innovent Presents Phase 1 Clinical Data of IBI351 as Monotherapy for Metastatic Colorectal Cancer at the 2023 ASCO Annual Meeting
Innovent Updates Phase 1B Data of IbI939 (Anti-Tigit Monoclonal Antibody) Combined with Sintilimab in Previously Untreated PD-L1-Selected NSCLC Jun 05
Innovent Announces the Second Breakthrough Therapy Designation by NMPA for Olverembatinib for the Treatment of Patients with SDH-Deficient GIST Jun 03
Innovent Biologics, Inc. Announces Phase 2 Clinical Study of Higher dose 9 mg Mazdutide (IBI362) in Chinese Adults with Obesity Achieved the 24-Week Primary Endpoint May 11
Innovent Biologics, Inc. Announces National Medical Products Administration Approves TYVYT (Sintilimab Injection) in Combination with Bevacizumab and Chemotherapy in Patients with EGFR-Mutated Non-Squamous Nsclc Who Progressed After EGFR-TKI Therapy May 10
No longer forecast to breakeven Apr 23
Full year 2022 earnings released Mar 29
Innovent Announces First Patient Dosed in a Phase 3 Clinical Trial (CLEAR) of Picankibart (Anti-IL23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Plaque Psoriasis Feb 16
Innovent Biologics, Inc. Announces First Participant Dosed in Phase 2 Study of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Associated Ophthalmopathy Feb 15
Innovent Announces Inclusion in the China National Reimbursement Drug List (NRDL) of TYVYT in Two New Indications, Olverembatinib for the First Listing, BYVASDA, HALPRYZA and SULINNO in Multiple New Indications Jan 19
Innovent Biologics, Inc. Announces First Participant Dosed in A Phase 3 Clinical Study (Dreams-1) of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes Jan 10
Innovent Biologics, Inc. Announces the National Medical Products Administration in China Has Accepted and Granted Priority Review Designation to the New Drug Application for Parsaclisib Jan 06
Forecast to breakeven in 2025 Dec 31 Innovent Biologics, Inc. Presents Phase Ib Clinical Data Update of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2022 European Society For Medical Oncology Immuno-Oncology Congress
Innovent and UNION Therapeutics Announce First Subject Dosed in a Chinese Clinical Phase I Study of the Novel PDE4 Inhibitor Orismilast (IBI353) Dec 05
Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (GLORY-1) of Mazdutide (IBI362) in Chinese Adults with Overweight or Obesity Nov 15
Innovent Biologics, Inc. Releases Results of a Phase 3 Clinical Study of Tafolecimab(IBI306)in Chinese Patients with non- Familial Hypercholesterolemia at the American Heart Association (AHA) Scirntific Sessions 2022 Nov 07
Innovent Announces First Patient Dosing in Australia in Phase I Study of IBI343 (Recombinant anti-Claudin18.2 Monoclonal Antibody-drug Conjugate) in Patients with Advanced Solid Tumors Oct 31
Innovent Announces Phase Ib Results of Higher-Dose Mazdutide (IBI362) in Chinese Participants with Overweight or Obesity Published in eClinicalmedicine Oct 19
Innovent Announces Phase Ib Results of Higher-Dose Mazdutide (IBI362) in Chinese Participants with Overweight or Obesity Published in eClinicalmedicine Oct 17 Innovent Biologics, Inc. Announces China NMPA Approves CYRAMZA (ramucirumab) for Treatment in Patients with Hepatocellular Carcinoma
Innovent Biologics, Inc. Announces Second Interim Analysis Results of the Randomized, Double-Blinded, Multi-Center Phase 3 ORIENT-31 Study Sep 08
Innovent Biologics, Inc. Announces First Participant Dosed in the Higher-Dose Cohort of A Phase 2 Clinical Trial of Mazdutide in Chinese Adults with Obesity Sep 07
Innovent Biologics, Inc. Announces First Participant Dosed in the Higher-Dose Cohort of A Phase 2 Clinical Trial of Mazdutide in Chinese Adults with Obesity Sep 06
No longer forecast to breakeven Aug 27
First half 2022 earnings released: CN¥0.65 loss per share (vs CN¥0.81 loss in 1H 2021) Aug 26
Innovent Biologics, Inc. Announces First Patient Dosing in Australia in Phase 1 Study of IBI363 (PD-1/IL-2 Bispecific Antibody Fusion Protein) in Patients with Advanced Malignancies Aug 24
Innovent Biologics, Inc. Announces First Subject Dosed in Phase 1 Study of IBI311 (Anti-IGF-1R Monoclonal Antibody) Aug 18
Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Moderate-to-Severe Plaque Psoriasis Met Primary Endpoint Aug 11
Innovent Biologics, Inc. Announces First Patient Dosed in Phase 1 Study of IBI324 (VEGF-A/Ang-2 Bispecific Antibody) in Patients with Diabetic Macular Edema Aug 08 株主還元 6IB DE Biotechs DE 市場 7D 8.0% 1.2% 2.3% 1Y 4.9% -5.6% 16.7%
株主還元を見る
業界別リターン: 6IB過去 1 年間で-5.6 % の収益を上げたGerman Biotechs業界を上回りました。
リターン対市場: 6IBは、過去 1 年間で16.7 % のリターンを上げたGerman市場を下回りました。
価格変動 Is 6IB's price volatile compared to industry and market? 6IB volatility 6IB Average Weekly Movement 6.3% Biotechs Industry Average Movement 5.7% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.5%
安定した株価: 6IB 、 German市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: 6IBの 週次ボラティリティ ( 6% ) は過去 1 年間安定しています。
会社概要 バイオ医薬品会社であるイノベント・バイオロジクス社は、中華人民共和国において、がん、眼科、自己免疫疾患、心血管・代謝疾患の分野におけるモノクローナル抗体やその他の医薬品資産の開発・商業化を行っている。ヒト型抗PD-1モノクローナル抗体Tyvyt、完全ヒト型抗VEGFモノクローナル抗体BYVASDA、組換えマウス/ヒト型キメラ抗CD20モノクローナル抗体HALPRYZAを提供している；ヒト型抗ヒトTNF-aモノクローナル抗体SULINNO、選択的FGFR阻害剤Pemazyre、新規BCR-ABL TKであるOlverembatinib、VEGF受容体2拮抗剤Cyramza、選択的かつ強力なRETキナーゼ阻害剤Retsevmo。また、完全ヒトBCMA CAR T細胞治療薬IBI-326、経口PI3Kd阻害薬IBI-376、KRASG12C阻害薬IBI-351、repressor of silencing 1/TRK チロシンキナーゼ阻害薬IBI-344、CEACAM5を標的とするADC IBI-126も開発中である；新規抗プロテイン転換酵素サブチリシン／ケキシン9型モノクローナル抗体IBI-306、グルカゴン様ペプチド-1受容体／グルカゴン受容体デュアルアゴニストIBI-362、新規長時間作用型抗IL-23薬IBI-112。さらに、新規抗LAG3モノクローナル抗体IBI-110、新規抗TIGITモノクローナル抗体IBI-939、抗CTLA-4モノクローナル抗体IBI-310、新規LAG3/PD-L1二重特異性抗体IBI-323、PD-1/IL-2二重特異性抗体融合タンパク質の可能性のあるIBI-363、組換え抗CLDN18.2モノクローナルADC、および抗VEGF/補体二重特異性融合タンパク質の可能性があるIBI-302である。さらに、後期段階の新規非プリン型キサンチンオキシダーゼ阻害剤IBI-128、強力かつ選択的な次世代PDE4阻害剤IBI-353、組換え抗IGF-1Rモノクローナル抗体IBI-311を開発している。さらに、医薬品の販売、コンサルティング、研究開発サービスも提供している。イノベント・バイオロジクス社は2011年に法人化され、中華人民共和国の蘇州に本社を置いている。
もっと見る Innovent Biologics, Inc. 基礎のまとめ Innovent Biologics の収益と売上を時価総額と比較するとどうか。 6IB 基礎統計学 時価総額 €7.18b 収益（TTM） -€168.67m 売上高(TTM ) €981.56m
収益と収入 最新の決算報告書（TTM）に基づく主な収益性統計 6IB 損益計算書（TTM） 収益 CN¥7.46b 売上原価 CN¥2.12b 売上総利益 CN¥5.34b その他の費用 CN¥6.62b 収益 -CN¥1.28b
一株当たり利益（EPS） -0.78 グロス・マージン 71.58% 純利益率 -17.18% 有利子負債／自己資本比率 25.8%
6IB の長期的なパフォーマンスは？
過去の実績と比較を見る
企業分析と財務データの現状 データ 最終更新日（UTC時間） 企業分析 2025/02/12 01:15 終値 2025/02/12 00:00 収益 2024/06/30 年間収益 2023/12/31
データソース 企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
パッケージ データ タイムフレーム 米国ソース例 会社財務 10年 アナリストのコンセンサス予想 +プラス3年 市場価格 30年 所有権 10年 マネジメント 10年 主な進展 10年
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら 。
分析モデルとスノーフレーク このレポートの作成に使用した分析モデルの詳細は、Githubページで ご覧いただけます。また、レポートの使用方法に関するガイドや 、Youtubeでのチュートリアルも ご用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについて ご紹介します。
業界およびセクターの指標 私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋 Innovent Biologics, Inc. 28 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。55
アナリスト 機関 Wai Chak Yuen BOCI Research Ltd. Linda Lu BOCI Research Ltd. Bo Li BofA Global Research
52 その他のアナリストを表示 
